MME Agnès MOUTON-GENSBURGER

Rhumatologue

RPPS 10000240647

✨ Profil synthétique

IA · 19/05/2026

MME Agnès MOUTON-GENSBURGER est une rhumatologue dont les publications PubMed couvrent divers aspects de la rhumatologie, notamment l'épidémiologie, la pharmacovigilance et l'économie de la santé. Ses travaux portent également sur les biomarqueurs et les auto-anticorps, ainsi que sur la qualité de vie et les mesures de résultats rapportés par les patients (PROMs).

Expertises présumées

Épidémiologie des maladies rhumatismales
Pharmacovigilance en rhumatologie
Biomarqueurs en rhumatologie
Auto-anticorps
Économie de la santé en rhumatologie
Qualité de vie des patients rhumatismaux
PROMs (Patient-Reported Outcome Measures)

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Pulmonary Arterial Hypertension Incidence in Patients With Systemic Sclerosis Treated With Bosentan for Digital Ulcers: Evidence From the SPRING-SIR Registry

The Journal of rheumatology · 2025

📚 5 citations🎯 RCR 2.38

Lire l'abstract Crossref ↓

ObjectiveBosentan (BOS) is approved for treating pulmonary arterial hypertension (PAH) and preventing digital ulcers (DU) in systemic sclerosis (SSc). Our study aimed to evaluate whether BOS prescribed for DU could reduce the incidence of PAH in a large SSc cohort from the Systemic Sclerosis Progression Investigation (SPRING) registry.MethodsPatients with SSc from the SPRING registry, meeting 2013 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria with data on PAH onset, DU status, BOS exposure, and at least 1 year of follow-up between 2015 and 2020, and having no known PAH at baseline, were included. PAH was diagnosed with right heart catheterization during the follow-up, and its incidence rate (IR) was calculated. Kaplan-Meier curves were determined, and multivariate regression identified PAH risk factors.ResultsAmong 727 eligible patients with SSc, followed for a median of 2.0 years, 54 (7.4%) developed PAH (IR 3.71 per 100 patient-years [PYs]). Patients with DU who were never exposed to BOS had a higher incidence of PAH (IR 4.90 per 100 PYs) compared to those exposed to BOS, whose rates matched those without DU and who were never exposed to BOS. Risk factors independently associated with PAH development included DU (hazard ratio [HR] 1.86), age (HR 1.05), modified Rodnan skin score > 4 (HR 2.07), interstitial lung disease (HR 2.29), and acetylsalicylic acid treatment (HR 1.78).ConclusionIn our cohort, the presence of DU was confirmed as a leading risk factor for PAH development, and BOS use for DU prevention may reduce this risk. Only patients with DU who were not using BOS had an increased PAH incidence.

Development of a community-based peer-support intervention to improve contraceptive agency and diffuse self-injectable contraception in Uganda: Application of the human-centered design approach

BMC women's health · 2025

📚 4 citations🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Background The low use of self-injectable contraception, coupled with the recognition that many individuals need support beyond training to use self-care technologies successfully, suggests the need for innovative programming. We describe the participatory human-centered design process we used in two districts of Uganda to develop a community-based peer support intervention to improve women’s agency to make and act on contraceptive decisions and help diffuse self-injectable contraception. Methods The design team included multi-disciplinary researchers from Uganda and the United States, representatives of local community-based organizations and village health teams, and local women of reproductive age. The research group conducted 21 in-depth interviews, 12 observations, and six focus group discussions to understand women’s social support needs, contraceptive-seeking experiences, and communication channels. From these data, the design team derived insights into needs and opportunities to improve contraceptive agency and support self-injection use among interested women, spurring a creative idea-generation process to develop a large set of potential solutions. We collectively prioritized the most promising ideas into an integrated, theoretically informed intervention and subsequently prototyped, tested, and refined the intervention. Results Design insights included: women value information from experienced peers and want support to navigate uneven partner dynamics, conflicting contraceptive information, concerns about contraceptive-related side effects, and unreliable contraception services. The final intervention—called I-CAN (English) , Nsobola (Lusoga) , An Atwero (Langi)—engages experienced self-injection users as ‘mentors’ to support other women (‘mentees’) they recruit in community-based settings. Mentors provide informational, instrumental, appraisal, and emotional support tailored to the individual needs of mentees. This support is designed to improve mentees’ knowledge, consciousness of their rights related to contraception, self-efficacy, and perceived control related to contraceptive decision-making, self-injection self-efficacy, contraceptive access, and ability to act on preferences. Conclusions Our iterative human-centered design process incorporated diverse, lived experiences and scientific expertise and resulted in a peer support intervention with the potential to fill an important gap in contraception service delivery in Uganda. Our approach demonstrates that creating complex interventions to prioritize support for women’s agency related to contraception in line with a human rights-based approach and to spread new contraceptive methods is feasible.

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Nature medicine · 2025

📚 4 citations🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Cookies & analyse de trafic

MME Agnès MOUTON-GENSBURGER

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal22

Épidémiologie & registres11

Revue générale4

Pharmacovigilance3

Biomarqueurs / Auto-Ac2

Économie santé2

Qualité de vie / PROMs2

Sclérodermie2

Arthrite juvénile1

Gériatrie1

IA en rhumatologie1

Ostéoporose1

Revue / méta-analyse1

Vraie vie / RWE1

Partager cette fiche